Medical cannabis has moved from the margins of medicine to the mainstream over the past two decades. As clinical evidence has accumulated and as legal access has expanded across Canada, much of the United States, and parts of Europe, doctors are now prescribing it for a growing list of conditions where conventional treatments fall short or carry significant downsides. Below are seven of the most common health issues people pursue medical cannabis for, and what the research actually says about each one.

1. Anxiety Disorders

Anxiety is the second-most-common reason patients seek medical cannabis, but the relationship is more complicated than chronic pain. THC can reduce anxiety at low doses but worsen it at higher ones, while CBD appears to have anxiety-reducing effects across a wider dose range without the psychoactive component of THC.

Generalized anxiety disorder, social anxiety, and panic disorder are the conditions most often reported. Patients typically describe a calmer baseline mood, fewer racing thoughts, and easier sleep onset rather than dramatic symptom relief. That matches what researchers see in early clinical trials, where moderate effects on anxiety symptoms are common but not universal.

Strain selection and dose matter more here than for almost any other condition. CBD-dominant or balanced strains are usually preferred over high-THC options, and a clinically supervised approach typically produces better results than recreational self-medication, since clinicians can match cannabinoid ratios to the specific symptom pattern. Some patients use cannabis as a daily baseline anxiety reducer, while others reserve it for acute episodes such as social events, flights, or panic attack onset.

2. Chronic Pain

Chronic pain is the single most common reason people pursue medical cannabis. The reason is straightforward: long-term pain affects roughly 20 percent of adults globally, and conventional options like opioids, NSAIDs, and corticosteroids carry significant downsides when used over months or years.

A landmark review by the National Academies of Sciences, Engineering, and Medicine found substantial evidence that cannabis or cannabinoids are effective for treating chronic pain in adults. That conclusion places chronic pain in the strongest evidence category in the entire report.

The conditions most commonly treated under this umbrella include:

• Neuropathic pain from nerve damage, diabetes, or post-surgical injury
• Fibromyalgia and other widespread musculoskeletal pain syndromes
• Lower back pain that has not responded to physical therapy or NSAIDs
• Inflammatory pain from rheumatoid arthritis, osteoarthritis, and lupus

Many patients seek alternatives when standard treatments fall short. Clinics such as Apollo Cannabis treat pain conditions as a primary entry point for medical cannabis evaluation, especially when patients have already tried first-line drugs without success. The advantage cannabis offers here is not necessarily stronger pain relief than opioids but a different side-effect profile and a much lower addiction risk.

For inflammatory pain specifically, CBD has drawn attention from researchers studying its effect on rheumatoid arthritis symptoms. The mechanism appears to involve modulation of the endocannabinoid system, which regulates both pain perception and inflammation.

3. PTSD

Post-traumatic stress disorder is one of the conditions where the gap between patient-reported benefits and randomized clinical trial data is widest. Veterans, sexual assault survivors, and others with trauma-related symptoms have long reported that cannabis reduces nightmares, hypervigilance, and intrusive memories. The clinical trial picture is less settled, but consistent enough that several Canadian provinces and US states list PTSD as a qualifying condition.

The proposed mechanism involves the endocannabinoid system’s role in fear extinction. In simpler terms, cannabis appears to help the brain process and release traumatic memories rather than reactivate them. THC seems particularly relevant for nightmare suppression, which is one of the most disruptive PTSD symptoms, while CBD has been studied for its effect on conditioned fear responses.

Veterans Affairs Canada covers medical cannabis for veterans with a confirmed PTSD diagnosis, which has made this group one of the most studied populations for real-world outcomes. Reported reductions in nightmare frequency, alcohol use, and antidepressant dosing have been consistent enough that more rigorous trials are now underway.

4. Sleep Disorders

Insomnia and other sleep disorders sit between chronic pain and anxiety as common driving complaints, and they often overlap with both. Patients who can’t sleep usually have an underlying reason, whether pain, racing thoughts, restless legs, or trauma-related arousal, and cannabis tends to address those underlying causes more than the sleep itself.

The cannabinoids most studied for sleep have distinct effect profiles:

• THC reduces sleep latency and shortens REM sleep, which is why some patients report fewer dreams when using it before bed
• CBD supports sleep mainly by lowering anxiety and cortisol levels rather than acting as a direct sedative
• CBN is often marketed as a sedative cannabinoid, though human evidence remains thin

For shift workers, chronic pain patients, and people with treatment-resistant insomnia, medical cannabis is increasingly used as an alternative to traditional sleep medications, which carry their own dependence risks.

5. Multiple Sclerosis

Multiple sclerosis was one of the first conditions where cannabis-based medicine entered mainstream clinical use. Sativex, an oromucosal spray containing THC and CBD in a roughly equal ratio, has been approved in Canada and parts of Europe specifically for the treatment of MS-related spasticity, making it one of the few cannabis products approved as a prescription pharmaceutical.

The condition causes muscle stiffness, painful spasms, and bladder dysfunction in many patients, and conventional muscle relaxants often produce sedation severe enough to interfere with daily life. Cannabinoids tend to reduce spasticity with milder cognitive side effects in this population, which is why several MS societies now treat them as a legitimate adjunct to standard therapy.

Patients also report relief from neuropathic pain, sleep disturbance, and bladder urgency associated with MS, though the evidence for spasticity relief remains stronger than for these secondary symptoms.

6. Epilepsy

Epilepsy is the only condition for which a cannabis-derived drug has received full FDA approval in the United States. Epidiolex, a purified cannabidiol oral solution, was approved in 2018 for treatment-resistant seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year and older.

This was a significant moment for medical cannabis as a category. Until then, no plant-derived cannabinoid had passed the full FDA approval process. The trials showed clinically meaningful seizure reductions in children whose conditions had not responded to standard antiepileptic drugs, with some participants experiencing more than a 50 percent drop in seizure frequency.

Outside the FDA-approved indications, doctors and parents have used CBD off-label for other forms of refractory epilepsy with mixed but often encouraging results. CBD has a real, measurable effect on seizure activity in certain syndromes, even if the exact mechanism is still being mapped. For families dealing with severe pediatric epilepsies, this is one of the most important developments to come out of cannabinoid research in the past two decades.

7. Cancer-Related Symptoms

Cancer is rarely a single condition, and medical cannabis is rarely positioned as a treatment for cancer itself. Instead, it is used to manage the symptoms that come with the disease and its treatment, including:

• Chemotherapy-induced nausea and vomiting that does not respond to standard antiemetic medications
• Cancer-related pain, especially bone pain and chemotherapy-induced neuropathy
• Appetite loss and cachexia in advanced disease
• Anxiety, depression, and insomnia related to diagnosis or treatment

The National Cancer Institute’s expert review of cannabis and cannabinoids notes that two cannabinoid drugs, dronabinol and nabilone, have been FDA-approved for treating chemotherapy-induced nausea and vomiting in patients who have not responded to standard antiemetic therapy. Both predate the broader medical cannabis movement by decades and remain widely used in oncology today.

For patients in palliative care, the combined effect on appetite, sleep, mood, and pain can improve quality of life in ways that single-purpose medications cannot, often allowing reductions in opioid dosing as well.

Medical cannabis is not a cure for any of these conditions, and the evidence supporting its use varies considerably across them. For chronic pain, MS spasticity, certain childhood epilepsies, and chemotherapy nausea, the case is now backed by substantial clinical research. For anxiety, PTSD, and sleep disorders, the evidence is promising but less complete. The right starting point for anyone considering it is a consultation with a clinician who can match the cannabinoid profile, dose, and consumption method to the specific condition involved, rather than treating cannabis as a single product with one effect.

Photo: Mark Stebnicki via Pexels

CLICK HERE TO DONATE IN SUPPORT OF OUR NONPROFIT COVERAGE OF ARTS AND CULTURE